Potency (pEC50), maximum response (Emax), and α value (Emax relative to norepinephrine) of agonists at the human α1A-AR
| Ca2+ Release | cAMP | ECAR | |
|---|---|---|---|
| Norepinephrine | |||
| pEC50 | 8.58 ± 0.07 | 5.55 ± 0.05 | 7.36 ± 0.04 |
| Emax | 92.8 ± 1.7 | 27.3 ± 0.5 | 152.2 ± 1.1 |
| α | 1.00 (6) | 1.00 (5) | 1.00 (4) |
| Methoxamine | |||
| pEC50 | 7.44 ± 0.05 | 4.39 ± 0.06 | 6.95 ± 0.04 |
| Emax | 87.7 ± 1.6 | 25.7 ± 0.8 | 146.5 ± 0.9 |
| α | 0.95 (6) | 0.94 (5) | 0.96 (4) |
| Phenylephrine | |||
| pEC50 | 8.10 ± 0.06 | 4.93 ± 0.06 | 8.29 ± 0.07 |
| Emax | 91.7 ± 1.6 | 23.4 ± 0.6 | 148.3 ± 1.6 |
| α | 0.99 (6) | 0.86 (5) | 0.97 (4) |
| Oxymetazoline | |||
| pEC50 | 8.86 ± 0.10 | N.D. | 8.55 ± 0.05 |
| Emax | 78.4 ± 2.4 | N.D. | 146.6 ± 1.0 |
| α | 0.84 (6) | N.D. | 0.96 (4) |
| Cirazoline | |||
| pEC50 | 8.54 ± 0.12 | 6.89 ± 0.08 | 8.13 ± 0.03 |
| Emax | 97.0 ± 3.5 | 14.8 ± 0.5 | 148.5 ± 0.6 |
| α | 1.05 (6) | 0.54 (5) | 0.98 (4) |
| A61603 | |||
| pEC50 | 9.63 ± 0.06 | 7.59 ± 0.05 | 9.09 ± 0.05 |
| Emax | 97.4 ± 2.0 | 28.6 ± 0.5 | 147.6 ± 1.1 |
| α | 1.05 (6) | 1.05 (5) | 0.97 (4) |
N.D., not determined.